TW200304813A - Salts of organic acid - Google Patents

Salts of organic acid Download PDF

Info

Publication number
TW200304813A
TW200304813A TW092105092A TW92105092A TW200304813A TW 200304813 A TW200304813 A TW 200304813A TW 092105092 A TW092105092 A TW 092105092A TW 92105092 A TW92105092 A TW 92105092A TW 200304813 A TW200304813 A TW 200304813A
Authority
TW
Taiwan
Prior art keywords
salt
patent application
nateglide
scope
item
Prior art date
Application number
TW092105092A
Other languages
English (en)
Chinese (zh)
Inventor
Paul Allen Sutton
Richard Victor Vivilecchia
David John Parker
Marilyn De La Cruz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200304813A publication Critical patent/TW200304813A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW092105092A 2002-03-11 2003-03-10 Salts of organic acid TW200304813A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36317802P 2002-03-11 2002-03-11

Publications (1)

Publication Number Publication Date
TW200304813A true TW200304813A (en) 2003-10-16

Family

ID=27805267

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092105092A TW200304813A (en) 2002-03-11 2003-03-10 Salts of organic acid

Country Status (11)

Country Link
US (2) US20050234129A1 (https=)
EP (1) EP1483232A1 (https=)
JP (2) JP2005519949A (https=)
CN (1) CN1274668C (https=)
AR (1) AR038927A1 (https=)
AU (1) AU2003214112A1 (https=)
BR (1) BR0308316A (https=)
CA (1) CA2478599A1 (https=)
PE (1) PE20040158A1 (https=)
TW (1) TW200304813A (https=)
WO (1) WO2003076393A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7449519B2 (en) * 2003-02-18 2008-11-11 Konishi Co., Ltd. Curing resin, method for producing same and curing resin composition
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
HU227073B1 (hu) * 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
WO2005016315A1 (en) * 2003-08-14 2005-02-24 Ranbaxy Laboratories Limited Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
TWI340650B (en) 2004-01-21 2011-04-21 Otsuka Pharma Co Ltd Amine saly of carbostyril derivative
US20060004102A1 (en) * 2004-05-07 2006-01-05 Shlomit Wizel Polymorphic forms of nateglinide
MY147393A (en) 2005-09-14 2012-11-30 Takeda Pharmaceutical Administration of dipeptidyl peptidase inhibitors
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EP2305239A1 (fr) * 2009-09-24 2011-04-06 Assistance Publique, Hopitaux De Paris Neuroprotection retinienne par des inhibiteurs des canaux ioniques regules par la sous-unite SUR
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
CN103417971A (zh) * 2013-08-13 2013-12-04 深圳奥萨医药有限公司 二肽基肽酶抑制剂和b族维生素的药物组合物及用途
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
ES2100291T3 (es) * 1991-07-30 1997-06-16 Ajinomoto Kk Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos.
WO2000059865A1 (en) * 1999-04-06 2000-10-12 Ono Pharmaceutical Co., Ltd. 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AU1133901A (en) * 1999-10-08 2001-04-23 Novartis Ag Method of treating metabolic disorders
HUP0600522A2 (en) * 1999-12-23 2006-11-28 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina

Also Published As

Publication number Publication date
US20090143469A1 (en) 2009-06-04
CN1274668C (zh) 2006-09-13
JP2011006476A (ja) 2011-01-13
JP2005519949A (ja) 2005-07-07
PE20040158A1 (es) 2004-04-26
CA2478599A1 (en) 2003-09-18
BR0308316A (pt) 2004-12-28
WO2003076393A1 (en) 2003-09-18
AU2003214112A1 (en) 2003-09-22
EP1483232A1 (en) 2004-12-08
US20050234129A1 (en) 2005-10-20
AR038927A1 (es) 2005-02-02
CN1642904A (zh) 2005-07-20

Similar Documents

Publication Publication Date Title
TW200304813A (en) Salts of organic acid
JP5835910B2 (ja) ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
KR101345316B1 (ko) 당뇨병 치료용 디펩티딜 펩티다아제 억제제
KR101352588B1 (ko) 당뇨병 치료용 디펩티딜 펩티다아제 억제제
CN101616673A (zh) 2-[6-(3-氨基-哌啶-1-基)-3-甲基-2,4-二氧代-3,4-二氢-2h-嘧啶-1-基甲基]-4-氟-苄腈的用途
US20140142145A1 (en) Combinations comprising a dipeptidylpeptidase - iv inhibitor
EP1385549A2 (en) Combination of nateglinide or repaglinide with at least one further antidiabetic compound
WO2006084757A2 (en) Combination of ca/mg salt of valsartan with an antidiabetic agent
HK1102424B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents